The 10x Dosing Error: Units, Syringes, and Why Multidose Vials Keep Hurting People
The most consistently documented harm in the compounded GLP-1 market is not contamination or potency. It is arithmetic — and it is entirely preventable.
The short version
- Compounded GLP-1 products have been associated with 10-fold dosing mistakes caused by confusion over syringe measurement units.
- America's Poison Centers managed 22,966 GLP-1 exposure cases from 2019 through 2025, with most involving accidental therapeutic errors.
- The error comes from the gap between a dose written in milligrams and a syringe marked in units.
- Prefilled or single-dose presentations remove the step where the error occurs.
Brand-name GLP-1s arrive in a pen. You dial a number, press, and the device delivers the dose. Most compounded GLP-1s arrive as a multidose vial and a box of syringes, and the patient performs the measurement. That single difference is responsible for the most consistently documented category of harm in this market.
How the error happens
Your prescription is written in milligrams — 0.25 mg, 0.5 mg, 2.5 mg. Your syringe is marked in units, because insulin syringes are the cheap, available option and that is what gets shipped. Converting between the two requires knowing the concentration of your specific vial, which varies between pharmacies and sometimes between batches from the same pharmacy.
Get the decimal wrong in that conversion and the result is not a slightly high dose. It is a ten-fold dose. Compounded products have been specifically associated with 10-fold dosing mistakes caused by exactly this confusion over syringe measurement units.
Unit-to-milligram conversions in these formulations frequently involve a factor of ten. Misplacing one decimal place — or reading a mark on the syringe as a unit when it represents a tenth — produces a clean 10x error rather than a small one. That is what makes this failure mode so consistent.
What a 10x GLP-1 dose does
Severe and prolonged nausea and vomiting, dehydration, and in some cases hospitalisation. The poison center record includes compounded-product dosing mistakes among a broader picture of 22,966 GLP-1 exposure cases managed from 2019 through 2025, with call volume rising nearly 1,500% across the period. Most cases involved accidental therapeutic errors rather than intentional misuse.
Because these medications have a long half-life, an overdose is not something that resolves in a few hours. The effects persist for days.
Six checks that eliminate almost all of this
- Get the concentration in writing. Not just the dose. You need milligrams per millilitre for your specific vial. It should be on the label; if it is not, that is a red flag about the pharmacy.
- Have the pharmacy state your dose in syringe units. Ask them to convert it for you, in writing, for the vial you were actually sent. Do not do the arithmetic yourself if you can avoid it.
- Re-verify at every concentration change. A new vial at a different concentration with the same milligram dose means a different number of units. Titration steps and pharmacy changes are both high-risk moments.
- Photograph the vial label and your draw. If something goes wrong, the record matters for both your clinician and any report you file.
- Draw in daylight, not at the end of the day. Every case study of this error involves a rushed or tired patient reading small markings.
- Ask a second person to confirm the first few doses. Especially after any change in supplier, concentration, or dose tier.
Ask any provider how the medication is dispensed before you enrol
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Semaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkMarketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkInjectable-only program with flat monthly plan pricing. An oral option is advertised but has not launched.
See Gala pricing Paid partner linkThe structural fix
Every mitigation above is a workaround for a design problem. The dispensing format is the actual cause. Prefilled pens and single-dose presentations remove the patient-performed conversion entirely, and with it the entire error class.
When you compare providers, put dispensing format alongside price. A program that costs somewhat more and ships a prefilled presentation is buying you out of the most common documented harm in this market. That is worth money.
Contact your prescriber or a poison control center immediately — do not wait to see how you feel. Bring the vial, the syringe, and the label. Report the event to the FDA's MedWatch program afterward, including the pharmacy name and lot number.
Why this keeps happening
Multidose vials are cheaper to produce and ship than prefilled devices, and insulin syringes are inexpensive and universally available. The format persists because it is economical for the supplier, and the cost of the resulting errors falls on patients. Understanding that is the fastest way to see why asking about dispensing format is a reasonable thing to do before you hand over a card number.
Sources
- America's Poison Centers, GLP-1 agonist exposure case data 2019 through 2025.
- Drug Discovery Trends reporting on compounded GLP-1 dosing errors and syringe unit confusion.
- FDA adverse event reporting data for compounded semaglutide and tirzepatide, as of May 31, 2026.
- FDA MedWatch adverse event reporting program guidance.